Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Drug Targets
  4. Volume 26, Issue 2
  5. Article
Volume 26, Issue 2
  • ISSN: 1389-4501
  • E-ISSN: 1873-5592

Abstract

Background

Increased levels of inflammation markers in patients with kidney disease, particularly chronic kidney disease (CKD) is an important risk factor. This study explored whether the effect of more potent statins on inflammation in CKD patients is dose-dependent, whether there is any difference between the hydrophilic and lipophilic statins concerning their effects on inflammation markers in patients with CKD, and whether the duration of treatment with statins has any effect on markers of inflammation in these patients.

Methods

A systematic literature search of Scopus, PubMed, and ISI Web of Science databases from inception to August 2022 was performed. Eligible studies were stratified based on a target population, intervention duration, dosage and type of statins (high intensity statin and moderate/low intensity), and solubility of statins. Publication bias was evaluated using Begg’s regression asymmetry test for visual inspection of funnel plots. Non-linear effects of dosage of statins and treatment duration were also examined by fractional polynomial modeling.

Results

Meta-analysis of 10 RCTs (12 studies) on 264 patients with kidney disease and 254 controls showed a significant hs-CRP lowering effect of the dose of statin. Both hydrophilic and lipophilic statins had significant hs-CRP lowering effects. Meta-analysis of 6 publications (7 studies) evaluating the impact of statins on CRP in 235 patients and 197 control subjects showed a significant negative association between treatment with statins group and CRP levels.

Conclusion

Statin treatment decreases significantly the levels of CRP and hs-CRP in patients with kidney disease.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdt/10.2174/0113894501302428240909150925
2024-09-23
2025-01-18

  • From This Site

    /content/journals/cdt/10.2174/0113894501302428240909150925
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WilsonS. MoneP. JankauskasS.S. GambardellaJ. SantulliG. Chronic kidney disease: Definition, updated epidemiology, staging, and mechanisms of increased cardiovascular risk.J. Clin. Hypertens. (Greenwich)202123483183410.1111/jch.1418633455061
     [Google Scholar]
  2. De NicolaL. MinutoloR. Worldwide growing epidemic of CKD: Fact or fiction?Kidney Int.201690348248410.1016/j.kint.2016.05.00127521111
     [Google Scholar]
  3. LeveyA.S. CoreshJ. Chronic kidney disease.Lancet2012379981116518010.1016/S0140‑6736(11)60178‑521840587
     [Google Scholar]
  4. EknoyanG. LameireN. EckardtK. KasiskeB. WheelerD. LevinA. StevensP. BilousR. LambE. CoreshJ. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.Kidney Int.201331514
     [Google Scholar]
  5. VondenhoffS. SchunkS.J. NoelsH. Increased cardiovascular risk in patients with chronic kidney disease.Herz20244929510410.1007/s00059‑024‑05235‑438416185
     [Google Scholar]
  6. OrtizA. WannerC. GansevoortR. OrtizA. WannerC. GansevoortR.T. CozzolinoM. FliserD. GambaroG. OngA. RosenkranzA.R. RychlıkI. SarafidisP. TorraR. TuglularS. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: A position statement by the Council of the European Renal Association.Eur. J. Prev. Cardiol.202229172211221510.1093/eurjpc/zwac18635997796
     [Google Scholar]
  7. GoA.S. ChertowG.M. FanD. McCullochC.E. HsuC. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.N. Engl. J. Med.2004351131296130510.1056/NEJMoa04103115385656
     [Google Scholar]
  8. ChenW.W. ZhangX. HuangW.J. Role of neuroinflammation in neurodegenerative diseases (Review).Mol. Med. Rep.20161343391339610.3892/mmr.2016.494826935478
     [Google Scholar]
  9. TonelliM. SacksF. PfefferM. JhangriG.S. CurhanG. Biomarkers of inflammation and progression of chronickidney disease.Kidney Int.200568123724510.1111/j.1523‑1755.2005.00398.x15954913
     [Google Scholar]
  10. SungK.C. RyuS. ChangY. ByrneC.D. KimS.H. C-reactive protein and risk of cardiovascular and all-cause mortality in 268 803 East Asians.Eur. Heart J.201435271809181610.1093/eurheartj/ehu05924569028
     [Google Scholar]
  11. WatersD.D. VogtL. Lipids, inflammation, and chronic kidney disease: A SHARP perspective.Kidney Int.201893478478610.1016/j.kint.2017.11.03129571452
     [Google Scholar]
  12. IstvanE. Statin inhibition of HMG-CoA reductase: A 3-dimensional view.Atheroscler. Suppl.2003413810.1016/S1567‑5688(03)00003‑512714031
     [Google Scholar]
  13. GermanC.A. LiaoJ.K. Understanding the molecular mechanisms of statin pleiotropic effects.Arch. Toxicol.20239761529154510.1007/s00204‑023‑03492‑637084080
     [Google Scholar]
  14. KimK. GinsbergH.N. ChoiS.H. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins.Diabetes Metab. J.202246581781810.4093/dmj.2022.029536193731
     [Google Scholar]
  15. SahebkarA. WattsG.F. New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes.Clin. Ther.20133581082109810.1016/j.clinthera.2013.06.01923932550
     [Google Scholar]
  16. SahebkarA. WattsG.F. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: What can the clinician expect?Cardiovasc. Drugs Ther.201327655956710.1007/s10557‑013‑6479‑423913122
     [Google Scholar]
  17. MichaeliD.T. MichaeliJ.C. AlbersS. BochT. MichaeliT. Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.Am. J. Cardiovasc. Drugs202323547749510.1007/s40256‑023‑00594‑537486464
     [Google Scholar]
  18. ChamaniS. LiberaleL. MobasheriL. MontecuccoF. Al-RasadiK. JamialahmadiT. SahebkarA. The role of statins in the differentiation and function of bone cells.Eur. J. Clin. Invest.2021517e1353410.1111/eci.1353433656763
     [Google Scholar]
  19. ChruścielP. SahebkarA. Rembek-WieliczkoM. SerbanM.C. UrsoniuS. MikhailidisD.P. JonesS.R. MosteoruS. BlahaM.J. MartinS.S. RyszJ. TothP.P. LipG.Y.H. PencinaM.J. RayK.K. BanachM. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms.Atherosclerosis201625319420810.1016/j.atherosclerosis.2016.07.89727498397
     [Google Scholar]
  20. MollazadehH. TavanaE. FanniG. BoS. BanachM. PirroM. von HaehlingS. JamialahmadiT. SahebkarA. Effects of statins on mitochondrial pathways.J. Cachexia Sarcopenia Muscle202112223725110.1002/jcsm.1265433511728
     [Google Scholar]
  21. SahebkarA. KotaniK. SerbanC. UrsoniuS. MikhailidisD.P. JonesS.R. RayK.K. BlahaM.J. RyszJ. TothP.P. MuntnerP. LipG.Y.H. BanachM. Statin therapy reduces plasma endothelin-1 concentrations: A meta-analysis of 15 randomized controlled trials.Atherosclerosis2015241243344210.1016/j.atherosclerosis.2015.05.02226074317
     [Google Scholar]
  22. MikhailidisD. UndasA. LipG. MuntnerP. BittnerV. RayK. WattsG. HovinghG.K. RyszJ. KasteleinJ. SahebkarA. SerbanC. BanachM. Association between statin use and plasma D-dimer levels.Thromb. Haemost.2015114954655710.1160/TH14‑11‑093726017749
     [Google Scholar]
  23. SahebkarA. SerbanC. UrsoniuS. MikhailidisD.P. UndasA. LipG.Y.H. BittnerV. RayK.K. WattsG.F. HovinghG.K. RyszJ. KasteleinJ.J.P. BanachM. The impact of statin therapy on plasma levels of von Willebrand factor antigen.Thromb. Haemost.2016115352053210.1160/th15‑08‑062026632869
     [Google Scholar]
  24. StoneN.J. RobinsonJ.G. LichtensteinA.H. Bairey MerzC.N. BlumC.B. EckelR.H. GoldbergA.C. GordonD. LevyD. Lloyd-JonesD.M. McBrideP. SchwartzJ.S. SheroS.T. SmithS.C.Jr WatsonK. WilsonP.W.F. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J. Am. Coll. Cardiol.2014632525 Part B2889293410.1016/j.jacc.2013.11.00224239923
     [Google Scholar]
  25. BahramiA. ParsamaneshN. AtkinS.L. BanachM. SahebkarA. Effect of statins on toll-like receptors: A new insight to pleiotropic effects.Pharmacol. Res.201813523023810.1016/j.phrs.2018.08.01430120976
     [Google Scholar]
  26. SahebkarA., Kiaie, N., Gorabi, A. M., Mannarino, M. R., Bianconi, V., Jamialahmadi, T., Pirro, M., Banach, M. A comprehensive review on the lipid and pleiotropic effects of pitavastatin.Prog Lipid Res20218410112710.1016/j.plipres.2021.101127
     [Google Scholar]
  27. DiamantisE. KyriakosG. Quiles-SanchezL.V. FarmakiP. TroupisT. The Anti-Inflammatory Effects of Statins on Coronary Artery Disease: An Updated Review of the Literature.Curr. Cardiol. Rev.201713320921628462692
     [Google Scholar]
  28. MessowC.M. IslesC. Meta-analysis of statins in chronic kidney disease: Who benefits?QJM2017110849350010.1093/qjmed/hcx04028340216
     [Google Scholar]
  29. FellströmB.C. JardineA.G. SchmiederR.E. HoldaasH. BannisterK. BeutlerJ. ChaeD.W. ChevaileA. CobbeS.M. Grönhagen-RiskaC. De LimaJ.J. LinsR. MayerG. McMahonA.W. ParvingH.H. RemuzziG. SamuelssonO. SonkodiS. SüleymanlarG. TsakirisD. TesarV. TodorovV. WiecekA. WüthrichR.P. GottlowM. JohnssonE. ZannadF. ZannadF. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.N. Engl. J. Med.2009360141395140710.1056/NEJMoa081017719332456
     [Google Scholar]
  30. ChangJ.W. YangW.S. MinW.K. LeeS.K. ParkJ.S. KimS.B. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients.Am. J. Kidney Dis.20023961213121710.1053/ajkd.2002.3339312046033
     [Google Scholar]
  31. MärzW. GenserB. DrechslerC. KraneV. GrammerT.B. RitzE. StojakovicT. ScharnaglH. WinklerK. HolmeI. HoldaasH. WannerC. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.Clin. J. Am. Soc. Nephrol.2011661316132510.2215/CJN.0912101021493741
     [Google Scholar]
  32. MoherD. LiberatiA. TetzlaffJ. AltmanD.G. GroupP. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement.Int. J. Surg.20108533634110.1016/j.ijsu.2010.02.00720171303
     [Google Scholar]
  33. JadadA.R. MooreR.A. CarrollD. JenkinsonC. ReynoldsD.J.M. GavaghanD.J. McQuayH.J. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Control. Clin. Trials199617111210.1016/0197‑2456(95)00134‑48721797
     [Google Scholar]
  34. DerSimonianR. LairdN. Meta-analysis in clinical trials.Control. Clin. Trials19867317718810.1016/0197‑2456(86)90046‑23802833
     [Google Scholar]
  35. HigginsJ.P.T. ThompsonS.G. Quantifying heterogeneity in a meta-analysis.Stat. Med.200221111539155810.1002/sim.118612111919
     [Google Scholar]
  36. GrundyS.M. StoneN.J. BaileyA.L. BeamC. BirtcherK.K. BlumenthalR.S. BraunL.T. de FerrantiS. Faiella-TommasinoJ. FormanD.E. GoldbergR. HeidenreichP.A. HlatkyM.A. JonesD.W. Lloyd-JonesD. Lopez-PajaresN. NdumeleC.E. OrringerC.E. PeraltaC.A. SaseenJ.J. SmithS.C.Jr SperlingL. ViraniS.S. YeboahJ. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary.J. Am. Coll. Cardiol.201973243168320910.1016/j.jacc.2018.11.00230423391
     [Google Scholar]
  37. ClimentE. BenaigesD. Pedro-BotetJ. Hydrophilic or Lipophilic Statins?Front. Cardiovasc. Med.2021868758510.3389/fcvm.2021.68758534095267
     [Google Scholar]
  38. BeggC.B. MazumdarM. Operating characteristics of a rank correlation test for publication bias.Biometrics19945041088110110.2307/25334467786990
     [Google Scholar]
  39. Masajtis-ZagajewskaA. NowickiM. Effect of atorvastatin on iron metabolism regulation in patients with chronic kidney disease – a randomized double blind crossover study.Ren. Fail.201840170070910.1080/0886022X.2018.153598330741616
     [Google Scholar]
  40. Tugrul SezerM. KatirciS. DemirM. ErturkJ. AdanaS. KayaS. Short-term effect of simvastatin treatment on inflammatory parameters in peritoneal dialysis patients.Scand. J. Urol. Nephrol.200741543644110.1080/0036559070151724417853009
     [Google Scholar]
  41. ArabulM. GulluluM. YilmazY. AkdagI. KahveciogluS. Ali ErenM. DilekK. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease.Clin. Biochem.200841131055105810.1016/j.clinbiochem.2008.05.01018571502
     [Google Scholar]
  42. SawaraY. TakeiT. UchidaK. OgawaT. YoshidaT. TsuchiyaK. NittaK. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease.Intern. Med.200847171505151010.2169/internalmedicine.47.115918758125
     [Google Scholar]
  43. BurmeisterJ.E. MiltersteinerD.R. CamposB.M. Rosuvastatin in hemodialysis: Short-term effects on lipids and C-reactive protein.J. Nephrol.2009221838919229822
     [Google Scholar]
  44. LiX.Y. ChangJ.P. SuZ.W. LiJ.H. PengB.S. ZhuS.L. CaiA.J. ZhangJ. JiangY. How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study.Ther. Apher. Dial.201014330831410.1111/j.1744‑9987.2009.00783.x20609184
     [Google Scholar]
  45. WuC.K. YehC.F. ChiangJ.Y. LinT.T. WuY.F. ChiangC.K. KaoT.W. HungK.Y. HuangJ.W. Effects of atorvastatin treatment on left ventricular diastolic function in peritoneal dialysis patients—The ALEVENT clinical trial.J. Clin. Lipidol.201711365766610.1016/j.jacl.2017.02.01628506387
     [Google Scholar]
  46. VermaA. RangannaK.M. ReddyR.S. VermaM. GordonN.F. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease.Am. J. Cardiol.20059691290129210.1016/j.amjcard.2005.06.07416253600
     [Google Scholar]
  47. Dornbrook-LavenderK.A. JoyM.S. Denu-CioccaC.J. ChinH. HoganS.L. PieperJ.A. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis.Pharmacotherapy200525333534410.1592/phco.25.3.335.6159915843280
     [Google Scholar]
  48. GoicoecheaM de VinuesaSG LaheraV CachofeiroV Gómez-CampderáF VegaA AbadS Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.J American Soc. Nephrol.20061712 suppl 3S231S5
     [Google Scholar]
  49. FassettR.G. RobertsonI.K. BallM.J. GeraghtyD.P. CoombesJ.S. Effects of atorvastatin on biomarkers of inflammation in chronic kidney disease.Clin. Nephrol.2014812758510.5414/CN10809024321183
     [Google Scholar]
  50. IchiharaA. HayashiM. RyuzakiM. HandaM. FurukawaT. SarutaT. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus.Nephrol. Dial. Transplant.20021781513151710.1093/ndt/17.8.151312147804
     [Google Scholar]
  51. JoSH KooBK ParkJS KangHJ ChoYS KimYJ YounTJ ChungWY ChaeIH ChoiDJ SohnDW OhBH ParkYB ChoiYS KimHS Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial--a randomized controlled study.Am Heart J.20081553499
     [Google Scholar]
  52. JoyM.S. Dornbrook-LavenderK.A. ChinH. HoganS.L. Denu-CioccaC. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.Ann. Pharmacother.200842191510.1345/aph.1K40718000162
     [Google Scholar]
  53. KirmizisD. PapagianniA. DogrammatziF. SkouraL. BelechriA.M. AlexopoulosE. EfstratiadisG. MemmosD. Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis.J. Atheroscler. Thromb.201017121256126510.5551/jat.571020885069
     [Google Scholar]
  54. MachF. BaigentC. CatapanoA.L. KoskinasK.C. CasulaM. BadimonL. ChapmanM.J. De BackerG.G. DelgadoV. FerenceB.A. GrahamI.M. HallidayA. LandmesserU. MihaylovaB. PedersenT.R. RiccardiG. RichterD.J. SabatineM.S. TaskinenM-R. TokgozogluL. WiklundO. WindeckerS. AboyansV. BaigentC. ColletJ-P. DeanV. DelgadoV. FitzsimonsD. GaleC.P. GrobbeeD. HalvorsenS. HindricksG. IungB. JüniP. KatusH.A. LandmesserU. LeclercqC. LettinoM. LewisB.S. MerkelyB. MuellerC. PetersenS. PetronioA.S. RichterD.J. RoffiM. ShlyakhtoE. SimpsonI.A. Sousa-UvaM. TouyzR.M. NiboucheD. ZelveianP.H. SiostrzonekP. NajafovR. van de BorneP. PojskicB. PostadzhiyanA. KyprisL. ŠpinarJ. LarsenM.L. EldinH.S. ViigimaaM. StrandbergT.E. FerrièresJ. AgladzeR. LaufsU. RallidisL. BajnokL. GudjónssonT. MaherV. HenkinY. GuliziaM.M. MussagaliyevaA. BajraktariG. KerimkulovaA. LatkovskisG. HamouiO. SlapikasR. VisserL. DingliP. IvanovV. BoskovicA. NazziM. VisserenF. MitevskaI. RetterstølK. JankowskiP. Fontes-CarvalhoR. GaitaD. EzhovM. FoscoliM. GigaV. PellaD. FrasZ. Perez de IslaL. HagströmE. LehmannR. AbidL. OzdoganO. MitchenkoO. PatelR.S. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.Atherosclerosis201929014020510.1016/j.atherosclerosis.2019.08.01431591002
     [Google Scholar]
  55. VisserenF.L.J. MachF. SmuldersY.M. CarballoD. KoskinasK.C. BäckM. BenetosA. BiffiA. BoavidaJ.M. CapodannoD. CosynsB. CrawfordC. DavosC.H. DesormaisI. AngelantonioE.D. FrancoO.H. HalvorsenS. Richard HobbsF.D. HollanderM. JankowskaE.A. MichalM. SaccoS. SattarN. TokgozogluL. TonstadS. TsioufisK.P. van DisI. van GelderI.C. WannerC. WilliamsB. GroupE.S.C.S.D. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC).Rev. Esp. Cardiol. (Engl. Ed.)202275542910.1016/j.rec.2022.04.00335525570
     [Google Scholar]
  56. BaigentC. LandrayM.J. ReithC. EmbersonJ. WheelerD.C. TomsonC. WannerC. KraneV. CassA. CraigJ. NealB. JiangL. HooiL.S. LevinA. AgodoaL. GazianoM. KasiskeB. WalkerR. MassyZ.A. Feldt-RasmussenB. KrairittichaiU. OphascharoensukV. FellströmB. HoldaasH. TesarV. WiecekA. GrobbeeD. de ZeeuwD. Grönhagen-RiskaC. DasguptaT. LewisD. HerringtonW. MafhamM. MajoniW. WallendszusK. GrimmR. PedersenT. TobertJ. ArmitageJ. BaxterA. BrayC. ChenY. ChenZ. HillM. KnottC. ParishS. SimpsonD. SleightP. YoungA. CollinsR. InvestigatorsS. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial.Lancet201137797842181219210.1016/S0140‑6736(11)60739‑321663949
     [Google Scholar]
  57. AthyrosV.G. KatsikiN. KaragiannisA. MikhailidisD.P. Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?Expert Opin. Pharmacother.201516101449146110.1517/14656566.2015.105346426037614
     [Google Scholar]
  58. MihaiS. CodriciE. PopescuI.D. EnciuA.M. AlbulescuL. NeculaL.G. MambetC. AntonG. TanaseC. Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome.J. Immunol. Res.20182018111610.1155/2018/218037330271792
     [Google Scholar]
  59. NikolicD. BanachM. NikfarS. SalariP. MikhailidisD.P. TothP.P. AbdollahiM. RayK.K. PencinaM.J. MalyszkoJ. RyszJ. RizzoM. A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?Int. J. Cardiol.201316865437544710.1016/j.ijcard.2013.08.06024016544
     [Google Scholar]
  60. KandeloueiT. AbbasifardM. ImaniD. AslaniS. RaziB. FasihiM. ShafiekhaniS. MohammadiK. JamialahmadiT. ReinerŽ. SahebkarA. Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Mediators Inflamm.20222022112010.1155/2022/873236035125965
     [Google Scholar]
  61. RidkerP.M. TuttleK.R. PerkovicV. LibbyP. MacFadyenJ.G. Inflammation drives residual risk in chronic kidney disease: A CANTOS substudy.Eur. Heart J.202243464832484410.1093/eurheartj/ehac44435943897
     [Google Scholar]
  62. WangJ. ChenZ. QiuY. WuL. WangH. WuL. ZhaoL. XieD. Statins Have an Anti-Inflammation in CKD Patients: A Meta-Analysis of Randomized Trials.BioMed Res. Int.20222022111210.1155/2022/484269936317110
     [Google Scholar]
/content/journals/cdt/10.2174/0113894501302428240909150925
Loading
Statin Therapy and C-reactive Protein in Patients with Kidney Disease: A Systematic Review and Meta-analysis of Randomized Clinical Trials
Curr Drug Targets 26, 132 (2025); https://doi.org/10.2174/0113894501302428240909150925
/content/journals/cdt/10.2174/0113894501302428240909150925
/content/journals/cdt/10.2174/0113894501302428240909150925
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Review Article
Keyword(s): cardiovascular disease; CRP; hs-CRP; inflammation; kidney disease; Statins

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test